Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalopathy - Companies Involved in Therapeutics Development
BrainRepair UG
Celularity Inc
Gene Therapy Research Institution Co Ltd
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Mononuclear Therapeutics Ltd
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl
Encephalopathy - Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CL-2020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SLC2A1 for GLUT1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-0006X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLBM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Anemia and Hypoxic Ischemic Encephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalopathy - Dormant Projects
Encephalopathy - Discontinued Products
Encephalopathy - Product Development Milestones
Featured News & Press Releases
Apr 02, 2019: Mithra receives orphan drug desigtion from FDA for E4 in neotal encephalopathy treatment
Apr 02, 2019: Mithra receives orphan drug desigtion from FDA for E4 in neotal encephalopathy treatment
Jun 09, 2017: Mithra Receives Orphan Drug Desigtion From EMA For E4 In Neotal Encephalopathy
Mar 17, 2017: Sanofi awarded new funding to Moni Lab to study glucose transporter-1 deficiency syndrome
Dec 31, 2016: Defining the Spatial and Temporal Requirements for the Glucose Transporter-1 protein in Glut1 Deficiency Syndrome
Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Desigtions for Intravenous Canbidiol in the Treatment of Neotal Hypoxic-Ischemic Encephalopathy
Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Desigtion From FDA for Canbidiol for the Treatment of Neotal Hypoxic-Ischemic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Encephalopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Encephalopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Encephalopathy - Pipeline by BrainRepair UG, H1 2020
Encephalopathy - Pipeline by Celularity Inc, H1 2020
Encephalopathy - Pipeline by Gene Therapy Research Institution Co Ltd, H1 2020
Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H1 2020
Encephalopathy - Pipeline by Hope Biosciences LLC, H1 2020
Encephalopathy - Pipeline by Inflazome Ltd, H1 2020
Encephalopathy - Pipeline by JS Genetics Inc, H1 2020
Encephalopathy - Pipeline by Mesoblast Ltd, H1 2020
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H1 2020
Encephalopathy - Pipeline by Mononuclear Therapeutics Ltd, H1 2020
Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, H1 2020
Encephalopathy - Pipeline by Pfizer Inc, H1 2020
Encephalopathy - Pipeline by ProThera Biologics Inc, H1 2020
Encephalopathy - Pipeline by ReAlta Life Sciences Inc, H1 2020
Encephalopathy - Pipeline by SL Bigen Inc, H1 2020
Encephalopathy - Pipeline by Worphmed Srl, H1 2020
Encephalopathy - Dormant Projects, H1 2020
Encephalopathy - Discontinued Products, H1 2020